City of Hope has signed an exclusive worldwide licensing agreement with Scopus BioPharma Inc. to develop and commercialize a City of Hope first-in-class, targeted immuno-oncology gene therapy.
The University of Texas MD Anderson Cancer Center and Royal Philips are providing oncologists with evidence-based therapy and clinical trial guidance through Philips' oncology informatics solutions and MD Anderson's Precision Oncology Decision Support system.
Isoray Inc. has entered a research grant agreement with the University of Cincinnati Physicians Company for a study on treatment of recurrent head and neck cancers.
Opdivo (nivolumab) was approved by FDA for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.
Nyvepria (pegfilgrastim-apgf), a biosimilar to Neulasta (pegfilgrastim), received FDA approval.
Berubicin was granted Orphan Drug Designation by FDA for the treatment of malignant gliomas.
Atezolizumab in combination with bevacizumab was approved by FDA for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
Cyramza (Ramucirumab) was approved by FDA in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) mutations.
Piqray received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Sarclisa (isatuximab) was approved by the European Commission in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.
